The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Isis Pharmaceuticals
Approval Status: Approved August 1998
Treatment for: CMV Retinitis
General Information
Vitravene Injection for the local treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis.
The use of Vitravene does not provide treatment for systemic CMV disease.
Clinical Results
Vitravene injection is not a cure for CMV retinitis, and some immunocompromised patients may continue to experience progression of retinitis during and following treatment. Patients receiving Vitravene should be advised to have regular ophthalmologic follow-up examinations. Patients may also experience other manifestations of CMV disease despite Vitravene therapy.
Side Effects
Abdomianl pain, anemia, diarrhea, fever, headache, infection, nausea, pneumonia, rash, etc.
